1 week Ago By Defense World Staff
Invesco Ltd. acquired a new position in ClearPoint Neuro, Inc. (NASDAQ:CLPT – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC.
The fund acquired 247,977 shares of the company’s stock, valued at approximately $3,814,000. Invesco Ltd. owned about 0.
90% of ClearPoint Neuro at the end of the most recent reporting period. Several other hedge funds also recently made changes to their positions in CLPT. Vanguard Group Inc.
boosted its holdings in ClearPoint Neuro by 0.4% during the fourth quarter. Vanguard Group Inc.
now owns 1,248,393 shares of the company’s stock worth $19,200,000 after buying an additional 5,400 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of ClearPoint Neuro by 1.5% during the 3rd quarter.
Geode Capital Management LLC now owns 287,294 shares of the company’s stock worth $3,222,000 after acquiring an additional 4,170 shares in the last quarter. Conway Capital Management Inc. grew its holdings in shares of ClearPoint Neuro by 13.
9% in the 4th quarter. Conway Capital Management Inc. now owns 161,225 shares of the company’s stock worth $2,480,000 after acquiring an additional 19,725 shares during the last quarter.
Parsons Capital Management Inc. RI raised its position in shares of ClearPoint Neuro by 1.9% during the fourth quarter.
Parsons Capital Management Inc. RI now owns 141,573 shares of the company’s stock worth $2,177,000 after purchasing an additional 2,600 shares during the period. Finally, Trexquant Investment LP raised its position in shares of ClearPoint Neuro by 10.
3% during the fourth quarter. Trexquant Investment LP now owns 78,362 shares of the company’s stock worth $1,205,000 after purchasing an additional 7,290 shares during the period. Institutional investors and hedge funds own 30.
08% of the company’s stock. ClearPoint Neuro Trading Up 2.9 %Shares of ClearPoint Neuro stock opened at $14.
70 on Monday. ClearPoint Neuro, Inc. has a 1 year low of $5.
11 and a 1 year high of $19.22. The company has a market cap of $411.
31 million, a P/E ratio of -21.30 and a beta of 0.97.
The stock has a 50-day moving average price of $13.19 and a 200 day moving average price of $14.11.
ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.
15) by ($0.05). The company had revenue of $7.
77 million for the quarter, compared to analyst estimates of $8.23 million. ClearPoint Neuro had a negative return on equity of 62.
10% and a negative net margin of 59.64%. On average, equities analysts forecast that ClearPoint Neuro, Inc.
will post -0.66 earnings per share for the current fiscal year. Analyst Upgrades and DowngradesA number of equities analysts recently weighed in on the company.
B. Riley lifted their price target on ClearPoint Neuro from $15.00 to $20.
00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th. Stifel Nicolaus boosted their price target on shares of ClearPoint Neuro from $19.00 to $25.
00 and gave the company a “buy” rating in a report on Tuesday, April 1st. Finally, Lake Street Capital upped their price target on shares of ClearPoint Neuro from $17.00 to $30.
00 and gave the company a “buy” rating in a research report on Tuesday, January 21st.View Our Latest Stock Analysis on ClearPoint NeuroClearPoint Neuro Profile (Free Report)ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions.
The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.Further ReadingFive stocks we like better than ClearPoint NeuroWhat Is WallStreetBets and What Stocks Are They Targeting?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryGolden Cross Stocks: Pattern, Examples and Charts O’Reilly Automotive: An Anytime Buy for Buy-and-Hold InvestorsStock Analyst Ratings and Canadian Analyst RatingsChipotle Mexican Grill Serves Smoking Hot Entry Point in Q2Want to see what other hedge funds are holding CLPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ClearPoint Neuro, Inc.
(NASDAQ:CLPT – Free Report)..
